Business Wire

CA-NEXA3D

6.9.2022 16:01:47 CEST | Business Wire | Press release

Share
Nexa3D Brings Additive Production Solutions to IMTS 2022

Nexa3D, the leading maker of ultrafast professional and industrial polymer 3D printers, today announced its plans to exhibit at IMTS, taking place September 12-17 in Chicago, Illinois. For its first showing at IMTS, Nexa3D is bringing its full – and rapidly expanding - additive manufacturing portfolio to Chicago.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005132/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The full suite of Nexa3D additive manufacturing solutions will be showcased at IMTS 2022, Additive Manufacturing Pavilion, Booth #432504 (Photo: Business Wire)

Among the real-world use cases highlighted at the booth will be the work with Applied Rapid Technologies (ART), where Nexa3D will demonstrate the benefits of owning the industrial 3D printing fleet for an on-demand manufacturing operation that replaces traditional urethane casting. Ultrafast, high performance resin 3D printing enables companies like ART to serve its customers’ needs in a more cost-effective manner and at a fraction of the time typically associated with traditional manufacturing methods. “Being a service provider with the Nexa3D machines - having 8 of them online now - just gives us more flexibility to take on projects and turn them around quickly. For years, we called this rapid prototyping, but it has really morphed into additive manufacturing,” said Bruce LeMaster, Vice President of Manufacturing at Obsidian Solutions Group.

“Nexa3D’s rapidly expanding product portfolio of ultrafast industrial solutions for the entire product life cycle democratizes access to industrial strength additive manufacturing tools, materials, and workflows for the benefit of small and large users. With no end in sight to persisting supply chain shortages, small and large product companies are more ready than ever before to explore digital manufacturing solutions and we are here to assist,” said Avi Reichental, CEO, and co-founder of Nexa3D.

Nexa3D’s end-to-end validated workflows, comprising its NexaX software platform, expanding functional polymer materials, and automated post processing deliver orders of magnitude better throughput and total cost of ownership advantages to businesses that are seeking to nearshore or localize parts of their supply chain operations. The company plans to showcase its latest industrial shop printers including its flagship NXE 400 and NXE 200 ultrafast 3D printers alongside its xCure, and xClean post-processing tools. The company also plans to introduce several new functional resins at the show.

As part of its rapidly expanding portfolio of manufacturing solutions, Nexa3D also plans to demonstrate the full power of its ultrafast XiP 3D printer in a production cell configuration, showcasing industry leading throughput, cost effectiveness, and functional material selection, powered by its open source platform enabling hyperlocal, flexible manufacturing.

The company plans to commercially launch previously announced QLS 820 high-productivity industrial sintering solution along with a powder processing system at IMTS. Designed for higher operating temperatures and broader powder processing windows, the QLS 820 offers the highest part throughput in its class, delivering unprecedented production throughput and flexibility. The system is a compelling alternative to traditional injection molding, designed with integration-ready Industry 4.0, lights-out manufacturing capabilities.

Nexa3D plans to take center stage on Wednesday, Sept. 14 at 1:00PM alongside its customer, PepsiCo, to talk about the latest manufacturing innovations in packaging design and development made possible by its ultrafast NXE 400 3D printers. More information and registration details available here.

As part of IMTS, the company plans to make several significant product commercialization announcements throughout the week from the show floor.

To learn more about the additive manufacturing solutions Nexa3D plans to exhibit at IMTS view the media kit.

About Nexa3D

Nexa3D is passionate about digitizing supply chains sustainably. The company makes ultrafast polymer 3D printers that deliver up to 20x productivity gains to professionals and businesses of all sizes. Partnerships with world-class material suppliers and its open materials platform unlock the full potential of additively manufactured polymers for volume production. Automated software tools optimize the entire production cycle using process interplay algorithms that ensure part performance and production consistency, while reducing waste, energy, and minimizing carbon footprints.

For more information on Nexa3D and its products, visit the Nexa3D website, or connect socially on LinkedIn, Twitter, Facebook, and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005132/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye